加载中...

MedXY News - diabetes

MedXY AI/MedXY News/Tag: diabetes

MedXY News

EnglishTag

diabetes

57 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Teprotumumab for Thyroid Eye Disease Carries a Measurable Long-Term Dysglycemia Risk

Teprotumumab for Thyroid Eye Disease Carries a Measurable Long-Term Dysglycemia Risk

A large multinational cohort study found that teprotumumab use in thyroid eye disease was associated with higher risks of prediabetes, diabetes, and antidiabetes medication initiation over 5 years.

Section: Diabetes & EndocrinologyMay 4, 2026

Optimizing Delivery Timing for Obese Pregnancies: The Critical Role of Pre-Pregnancy Diabetes in Stillbirth Risk

Optimizing Delivery Timing for Obese Pregnancies: The Critical Role of Pre-Pregnancy Diabetes in Stillbirth Risk

A nationwide study reveals that pre-pregnancy BMI and diabetes status significantly influence gestational age-specific stillbirth risks, with obese diabetic women facing the highest absolute risks, necessitating tailored delivery timing str

Section: newsApr 27, 2026

uGMI: A More Accurate Alternative to HbA1c for Diabetes Management

uGMI: A More Accurate Alternative to HbA1c for Diabetes Management

The updated glucose management indicator (uGMI) significantly improves alignment with HbA1c, reducing discordance, particularly in high and low glucose ranges, offering clinicians a more reliable tool for diabetes monitoring.

Section: Diabetes & EndocrinologyApr 25, 2026

Produce Prescription for Diabetes Falls Short in Improving Health Outcomes

Produce Prescription for Diabetes Falls Short in Improving Health Outcomes

A randomized trial found that a $80 monthly produce prescription did not significantly improve HbA1c levels or reduce healthcare utilization in diabetic patients at risk of food insecurity.

Section: Diabetes & EndocrinologyApr 21, 2026

Genetic Variant Modulates Dietary Impact on Glucose Control: Inuit Study Reveals Key Insights

Genetic Variant Modulates Dietary Impact on Glucose Control: Inuit Study Reveals Key Insights

A Greenlandic study shows that Inuit with a specific sucrase-isomaltase gene variant have better glucose regulation on a Western diet compared to non-carriers, suggesting potential new diabetes treatments.

Section: Diabetes & EndocrinologyApr 19, 2026

Ticagrelor Falls Short: TUXEDO-2 Trial Challenges Antiplatelet Choice in Diabetic Patients With Multivessel Disease

Ticagrelor Falls Short: TUXEDO-2 Trial Challenges Antiplatelet Choice in Diabetic Patients With Multivessel Disease

The TUXEDO-2 trial reveals that ticagrelor did not meet noninferiority criteria compared with prasugrel in diabetic patients with multivessel coronary artery disease undergoing PCI. At 1 year, the primary composite endpoint of death, MI, st

Section: CardiologyApr 13, 2026

Semaglutide Shows Promise in Reducing Mental Illness Worsening in Patients with Depression and Anxiety, Swedish Study Finds

Semaglutide Shows Promise in Reducing Mental Illness Worsening in Patients with Depression and Anxiety, Swedish Study Finds

A landmark Swedish cohort study of 95,490 patients reveals that semaglutide is associated with a 42% lower risk of worsening mental illness in people with depression and anxiety, while other GLP-1 receptor agonists show varied effects. The

Section: Diabetes & EndocrinologyApr 13, 2026

Decoding the Diabetic Heart: Novel Proteomic Signatures of Heart Failure Risk in the ARIC Study

Decoding the Diabetic Heart: Novel Proteomic Signatures of Heart Failure Risk in the ARIC Study

A comprehensive review of the ARIC study’s identification of five unique proteomic markers—four novel—that specifically predict heart failure risk in patients with diabetes, offering new insights into lipid metabolism and inflammatory pathw

Section: CardiologyMar 23, 2026

Insulin Resistance and Hyperinsulinemia: The Hidden Drivers of Lung Function Decline in Diabetes

Insulin Resistance and Hyperinsulinemia: The Hidden Drivers of Lung Function Decline in Diabetes

A comprehensive study combining the German Diabetes Study data and Mendelian randomization establishes a causal link between insulin resistance and reduced lung function (FEV1 and FVC), positioning the lung as a critical target for metaboli

Section: Diabetes & EndocrinologyMar 20, 2026

The Changing Landscape of Mortality in Diabetes: A Shift from Cardiovascular Dominance to Cancer and Dementia

The Changing Landscape of Mortality in Diabetes: A Shift from Cardiovascular Dominance to Cancer and Dementia

This review analyzes multinational data showing a significant decline in cardiovascular mortality among diabetes patients, alongside a concerning rise in dementia-related deaths and the emergence of cancer as a leading cause of mortality in

Section: CardiologyMar 16, 2026

Is Prasugrel the New Gold Standard? Ticagrelor Fails Noninferiority in High-Risk Diabetic and STEMI Populations

Is Prasugrel the New Gold Standard? Ticagrelor Fails Noninferiority in High-Risk Diabetic and STEMI Populations

Recent data from the TUXEDO-2 and ISAR-REACT 5 trials suggest prasugrel may provide superior outcomes over ticagrelor in high-risk PCI patients, including those with diabetes and STEMI.

Section: CardiologyFeb 21, 2026

Produce Prescriptions Alone Fail to Improve Diabetes Outcomes: Lessons from a Major Pragmatic Trial

Produce Prescriptions Alone Fail to Improve Diabetes Outcomes: Lessons from a Major Pragmatic Trial

A large-scale randomized trial reveals that monthly produce subsidies do not significantly improve HbA1c or reduce healthcare utilization in food-insecure diabetes patients, suggesting that ‘Food is Medicine’ initiatives require more than j

Section: Diabetes & EndocrinologyFeb 20, 2026

Circadian Heart Rate Fluctuations: A Potent 21-Year Predictor of Mortality in Patients with Diabetes

Circadian Heart Rate Fluctuations: A Potent 21-Year Predictor of Mortality in Patients with Diabetes

A 21-year longitudinal study demonstrates that impaired circadian heart rate fluctuations, measured via 24-hour ambulatory monitoring, significantly predict cardiovascular and all-cause mortality in diabetes, offering a low-cost, accessible

Section: CardiologyFeb 4, 2026

Diminished Circadian Heart Rate Fluctuations: A Potent Predictor of 21-Year Mortality in Patients with Diabetes

Diminished Circadian Heart Rate Fluctuations: A Potent Predictor of 21-Year Mortality in Patients with Diabetes

A 21-year longitudinal study reveals that blunted circadian heart rate variability and nocturnal dipping are independent predictors of cardiovascular and all-cause mortality in type 1 and type 2 diabetes, offering a low-cost risk stratifica

Section: CardiologyFeb 4, 2026

Mind the Gap: Patients with Mental Disorders Face Significant Disparities in Diabetes Monitoring and Modern Therapies

Mind the Gap: Patients with Mental Disorders Face Significant Disparities in Diabetes Monitoring and Modern Therapies

A massive systematic review of 5.5 million patients reveals that those with mental disorders receive significantly lower quality diabetes care, including less frequent monitoring and a 74% lower likelihood of being prescribed GLP-1 receptor

Section: Diabetes & EndocrinologyJan 30, 2026

Donor Diabetes Status Does Not Compromise DMEK Outcomes: 1-Year Results from the DEKS Randomized Clinical Trial

Donor Diabetes Status Does Not Compromise DMEK Outcomes: 1-Year Results from the DEKS Randomized Clinical Trial

The Diabetes Endothelial Keratoplasty Study (DEKS) confirms that donor diabetes status has no clinically significant impact on 1-year graft success rates or endothelial cell loss after Descemet membrane endothelial keratoplasty (DMEK), faci

Section: Diabetes & EndocrinologyJan 11, 2026

Beyond eGFR and UACR: kidneyintelX.dkd Refines Risk Stratification and Monitors Treatment Response in Diabetic Kidney Disease

Beyond eGFR and UACR: kidneyintelX.dkd Refines Risk Stratification and Monitors Treatment Response in Diabetic Kidney Disease

A post-hoc analysis of the CANVAS and CREDENCE trials reveals that the kidneyintelX.dkd score significantly improves risk reclassification and monitors the therapeutic impact of canagliflozin in patients with type 2 diabetes and chronic kid

Section: Diabetes & EndocrinologyDec 31, 2025

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immu

Section: Diabetes & EndocrinologyDec 29, 2025

Beyond Insulin Resistance: Why Diabetes Status Dictates the Cardiovascular Risk of the Triglyceride-Glucose Index

Beyond Insulin Resistance: Why Diabetes Status Dictates the Cardiovascular Risk of the Triglyceride-Glucose Index

A prospective ARIC cohort study reveals that diabetes fundamentally modifies the relationship between the triglyceride-glucose (TyG) index and subclinical myocardial injury, shifting the risk profile from an L-shaped to a J-shaped associati

Section: CardiologyDec 25, 2025

Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

This analysis of the EAST-AFNET 4 trial highlights that early rhythm control therapy’s cardiovascular benefits and safety are consistent regardless of diabetes or obesity status in atrial fibrillation patients.

Section: CardiologyDec 23, 2025

Prev 1 2 3 Next